ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model
A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The
Journal of Nuclear Medicine. The results of the murine study indicate that radionuclide therapy promotes prostate cancer immunogenicity, provoking a cellular response that makes the tumors more receptive to immunotherapy.
Prostate cancer is generally viewed as an immunological cold cancer in which immunotherapies only have moderate success. Increasing prostate cancer immunogenicity with prostate-specific membrane antigen (PSMA) radionuclide therapy, however, might render immunotherapies more successful. In our research we sought to exploit this effect by combining radionuclide therapy with immunotherapy in a mouse model of prostate cancer.